Abstract Changes in classical and nonclassical HLA class I as well as HLA class II antigens
have been identified in malignant lesions. These changes, which are described in this …

Resistance to chemotherapeutic drugs is the major hindrance in the successful cancer
therapy. The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of …

Objectives Activated Wnt signalling with decreased expression of endogenous inhibitors has
recently been characterised as a central pathomechanism in systemic sclerosis (SSc) …

Innate and acquired resistance towards the conventional therapeutic regimen imposes a
significant challenge for the successful management of cancer for decades. In patients with …

Genome-wide reduction in 5-methylcytosine is an epigenetic hallmark of human
tumorigenesis. Experimentally induced hypomethylation in mice promotes genomic …

Cancer as one of the leading causes of human deaths has always been one of the main
health challenges in the world. Despite recent advances in therapeutic and diagnostic …

Background & Aims: Interleukin 6 (IL-6)-mediated signal transducers and activators of
transcription 3 (STAT-3) phosphorylation (activation) is aberrantly sustained in …

Importance of the field: TNF-related apoptosis-inducing ligand (TRAIL) is a member of the
TNF family of cytokines, which can induce apoptotic cell death in a variety of tumor cells by …

Since its identification in 1995, TNF-Related apoptosis-inducing ligand (TRAIL) has sparked
growing interest in oncology due to its reported ability to selectively trigger cancer cell death …

TRAIL is a promising anticancer agent due to its ability to selectively induce apoptosis in
established tumor cell lines but not nontransformed cells. Herein, we demonstrate a role for …